|
Jul 25
|
Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma
|
|
Jul 2
|
Checkpoint Therapeutics Resubmits Biologics License Application for Cosibelimab, Launches $12 Million Direct Share Offering
|
|
Jul 2
|
Checkpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
|
Jul 2
|
Checkpoint Therapeutics Announces Biologics License Application Resubmission for Cosibelimab
|
|
Jun 24
|
Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission
|
|
May 13
|
Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
|
|
May 12
|
Checkpoint Therapeutics First Quarter 2024 Earnings: US$0.32 loss per share (vs US$0.89 loss in 1Q 2023)
|
|
May 10
|
Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates
|
|
Mar 24
|
Checkpoint Therapeutics Full Year 2023 Earnings: Misses Expectations
|
|
Mar 22
|
Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
|
|
Mar 18
|
Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors
|
|
Jan 11
|
Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference
|
|
Dec 19
|
Checkpoint Therapeutics, Inc.'s (NASDAQ:CKPT) Profit Outlook
|
|
Dec 18
|
UPDATE 1-US FDA declines to approve Checkpoint Therapeutics' skin cancer therapy
|
|
Dec 18
|
U.S. Food and Drug Administration Issues Complete Response Letter for Cosibelimab Solely Due to Inspection Findings at Third-Party Manufacturer
|
|
Dec 5
|
Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent Issuance
|
|
Jun 28
|
Checkpoint Therapeutics Announces Presentation of New Cosibelimab Pharmacokinetic Data Supporting Extended-Interval Dosing
|